Citi, Stifel Bullish on Olema (OLMA) Despite COO Departure [Yahoo! Finance]
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: Yahoo! Finance
Olema Pharmaceuticals Inc. (NASDAQ: OLMA ) is one of 15 stocks with the biggest hedge fund momentum , after gaining 28 hedge fund holders during the fourth quarter of 2025. On February 19, Citi analyst Yigal Nochomovitz maintained a Buy rating on Olema Pharmaceuticals Inc. (NASDAQ:OLMA) and set a price target of $60. Meanwhile, on February 11, Stifel initiated coverage of Olema Pharmaceuticals Inc. (NASDAQ:OLMA) with a Buy rating and $48 price target, saying that it conservatively modeled peak sales estimates of $3.1B in 2035 for lead asset palazestrant. The analyst added that endocrine therapy could be “a $20 billion plus global market opportunity with plenty of room for many big players.” These analyst actions followed a January 30 announcement from Olema Pharmaceuticals Inc. (NASDAQ:OLMA) that Shane Kovacs, its Chief Operating Officer and Chief Financial Officer, had departed the company, effective the same day. The company stated that Kovacs is leaving to pursue new opportuniti
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- Olema Pharmaceuticals (OLMA) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
- Olema Pharmaceuticals (OLMA) had its price target raised by JPMorgan Chase & Co. from $55.00 to $58.00. They now have an "overweight" rating on the stock.MarketBeat
- Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]Yahoo! Finance
- Olema Pharmaceuticals (OLMA) had its price target lowered by The Goldman Sachs Group, Inc. from $38.00 to $27.00. They now have a "buy" rating on the stock.MarketBeat
- Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual MeetingGlobeNewswire
OLMA
Earnings
- 3/16/26 - Beat
OLMA
Sec Filings
- 3/16/26 - Form 144
- 3/16/26 - Form 144
- 3/16/26 - Form S-8
- OLMA's page on the SEC website